Publication | Open Access
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
373
Citations
14
References
2023
Year
Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease. (Funded by AbbVie; U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1